Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next DecadeThe Motley Fool • 10/26/25
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/24/25
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?Zacks Investment Research • 10/24/25
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady GrowthThe Motley Fool • 10/23/25
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma SectorThe Motley Fool • 10/22/25
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 10/22/25
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant RecipientsPRNewsWire • 10/21/25
Here's What to Expect From AbbVie's Oncology Segment in Q3 EarningsZacks Investment Research • 10/20/25
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF InhibitorPRNewsWire • 10/20/25
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?Zacks Investment Research • 10/14/25
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel DiseasePRNewsWire • 10/13/25
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid TumorsPRNewsWire • 10/13/25
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?Zacks Investment Research • 10/09/25
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst MoisturizerPRNewsWire • 10/09/25